News | December 01, 2014

Advances in Pediatric Heart Disease Highlighted at AHA

Experts from The Children's Hospital of Philadelphia explain the advances

3-D Printing, Congenital heart, The Children's Hospital of Philadelphia (CHOP)

December 1, 2014 — Physician-researchers from the Cardiac Center at The Children’s Hospital of Philadelphia (CHOP) presented new findings on pediatric cardiovascular disease at the American Heart Association’s Scientific Sessions 2014 in Chicago. Among other topics, they investigated using automated external defibrillators in infants, long-term cardiac risk in surgical survivors of the Fontan operations for congenital heart disease, and whether centers that perform more cardiac catheterizations tend to have better outcomes.

Pediatric cardiologist Yoav Dori, M.D., Ph.D., delivered a lecture on fabricating innovative 3-D models of abnormal heart structures in individual patients to assist clinicians in planning complex heart surgery for each patient. Here is his summary of this presentation:

3-D Printing of Congenital Heart Disease

As the procedures performed for patients with congenital heart disease (CHD) become more complex, so does the need for better methods and tools for clinicians to understand complex three-dimensional anatomy and spatial relationships. 3-D rapid prototyping is quickly becoming a powerful tool to aid in planning, simulating, and teaching complex corrective CHD procedures. This review discusses the use of 3-D rapid prototyping in patients with CHD.

Children’s Hospital clinicians also moderated scientific sessions and participated on expert panels. Below are summaries of some of the research presented at abstract sessions.

Should AEDs Be Used in Infants?
While automated external defibrillators (AEDs) have improved survival rates for out-of-hospital cardiac arrests in many patient subgroups, little is known about the safety and efficacy of AEDs in infants. Joseph Rossano, M.D., and colleagues searched the scientific literature for relevant studies of the use of external defibrillation in infants with pediatric arrhythmias. The data from clinical studies on AED use in infants are limited, with no randomized clinical trials. However, research supports the accuracy of AEDs in recognizing pediatric arrhythmias, and two case reports demonstrated the successful use of AEDs in infants. Dosage studies suggest that further research is needed to determine the most effective defibrillation doses in children. Because the available evidence suggests that AEDs are safe and effective in infants, and because survival is unlikely in the absence of prompt defibrillation, the authors recommend the use of AEDs in infants with suspected cardiac arrest. 
Joseph Rossano et al, What is the Evidence for the Use of Automated External Defibrillators in Infants?

 

Does Volume of Cardiac Caths Correlate with Better Outcomes?
In many types of cardiology procedures, there is an association between higher institutional volume and improved outcomes. Andrew C. Glatz, M.D., and colleagues investigated whether such a relationship occurs in congenital cardiac catheterization. The study team identified all congenital cardiac catheterizations from 2011 to 2013 at 64 institutions in the IMPACT (Improving Pediatric and Adult Congenital Treatment) Registry. Of the 33,825 catheterizations, a major adverse event occurred in 711 cases (2.1%). In unadjusted analysis, the risk of adverse events was lower in centers that perform more catheterizations for congenital heart disease. However, after adjusting for patient- and procedure-level factors, there was no significant association between center volume and outcome. The researchers added that the hospital sample size and low event rate may have limited their ability to detect significant differences.
Andrew Glatz et al, Relationship between Hospital Procedure Volume and Complications Following Cardiac Catheterization: A Report from the IMPACT Registry

 

Fontan Survivors with PA-IVS Remain at Risk for Late Myocardial Infarction
A subset of newborns with the congenital heart condition pulmonary atresia with intact ventricular septum (PA-IVS) are at risk of myocardial infarction (MI) and sudden death because of abnormal coronary circulation. To avoid this, such patients may undergo single ventricle palliation and ultimately the Fontan procedure. Data are lacking, however, on the survivors’ risk of long-term myocardial ischemia. Adam Small, M.D., Therese Giglia, M.D., and colleagues performed a retrospective review of CHOP patients who underwent the Fontan procedure for PA-IVS between 1985 and 2013. There were 46 patients who met inclusion criteria for the study, with median follow-up of 3.5 years (range 0-27.9 y) after the Fontan. There were two early deaths after Fontan. Five patients had evidence of late ischemia: two had non-fatal MI at 16.9 and 18.8 years post-Fontan and three additional patients had evidence of ischemia on stress test and/or cardiac MRI without clinical evidence of MI. No patient had traditional risk factors for atherosclerotic coronary disease, and there were no late deaths or sustained ventricular tachycardia. Patients with PA-IVS and single-ventricle palliation remain at risk for long-term myocardial ischemia. Further study is needed to define risk factors for ischemic outcomes.

For more information: www.chop.edu

Related Content

Philips Receives FDA PMA for HeartStart OnSite and HeartStart Home Defibrillators

The Philips HeartStart OnSite automated external defibrillator. Image courtesy of Philips Healthcare.

Technology | Defibrillator Monitors | June 19, 2019
Philips announced the U.S. Food and Drug Administration (FDA) has approved the company’s premarket approval (PMA)...
HeartHero Personal Automated External Defibrillator Wins ACC.19 Innovation Challenge
News | Defibrillator Monitors | April 05, 2019
April 5, 2019 — Medical device startup HeartHero was the winner in the Innovation Challenge at the...
Stryker has recalled its LifePak 15 defibrillator-monitor system because it may lock up after delivering a shock to a patient. The defibrillator was originally made by Physio-Control, before being purchased by Stryker.

Stryker has initiated a field action to prevent its LifePak 15 defibrillator-monitor systems from locking up after delivering a shock to a patient. 

Feature | Defibrillator Monitors | February 04, 2019
February 4, 2019 — Stryker announced Feb.
The Zoll LifeVest wearable defibrillator was the subject of the VEST Trial

The Zoll LifeVest wearable defibrillator system was evaluated in the late-breaking VEST Trial presented at ACC 2018 earlier this year.

Feature | Defibrillator Monitors | July 10, 2018 | Michael J. Mirro, M.D.
Following the...
Rice University Students Improve AED Operation With Needle Pad

The automated external defibrillator add-on developed by Rice University students is a pad of needles that break through the skin's natural impedance barrier to deliver an electric shock to the heart of a patient in cardiac arrest. (Credit: Jeff Fitlow/Rice University)

News | Defibrillator Monitors | April 16, 2018
The skin presents a formidable barrier to life-saving defibrillators, but a team of students from Rice University...
Zoll Canada Equipping Province of Québec Paramedic Services with X Series Monitor/Defibrillators
News | Defibrillator Monitors | October 16, 2017
October 16, 2017 — Zoll Canada, a subsidiary of Zoll Medical Corp., announced it has won the tender to equip all ambu
Physio-Control Launches HeartSine samaritan PAD 360P Automated External Defibrillator in United States
Technology | Defibrillator Monitors | April 24, 2017
Physio-Control announced April 19 that the company’s HeartSine samaritan PAD 360P (SAM 360P) fully automatic external...
AEDs, automated external defibrillators, requirements, U.S. schools, JACC study
News | Defibrillator Monitors | March 30, 2017
Automated external defibrillators (AEDs) are associated with increased survival of sudden cardiac arrest when installed...
Philips, FDA, class I recall, HeartStart MRx Monitor/Defibrillator
News | Defibrillator Monitors | March 28, 2017
Philips and the U.S. Food and Drug Administration (FDA) announced the company has initiated a recall of its HeartStart...
Overlay Init